IMMUNOPRECISE ANTIBODIES LTD (IPA)

CA45257F2008 - Common Stock

0.548  +0.03 (+5.4%)

After market: 0.5256 -0.02 (-4.09%)

Fundamental Rating

2

IPA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. IPA may be in some trouble as it scores bad on both profitability and health. IPA is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IPA has reported negative net income.
IPA had a negative operating cash flow in the past year.
In the past 5 years IPA always reported negative net income.
In the past 5 years IPA always reported negative operating cash flow.

1.2 Ratios

IPA's Return On Assets of -45.92% is on the low side compared to the rest of the industry. IPA is outperformed by 85.96% of its industry peers.
With a Return On Equity value of -84.27%, IPA is not doing good in the industry: 78.95% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -45.92%
ROE -84.27%
ROIC N/A
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

IPA has a Gross Margin of 50.27%. This is comparable to the rest of the industry: IPA outperforms 57.89% of its industry peers.
IPA's Gross Margin has been stable in the last couple of years.
IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%

More info and screens

1

2. Health

2.1 Basic Checks

IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IPA has more shares outstanding
Compared to 1 year ago, IPA has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.37, we must say that IPA is in the distress zone and has some risk of bankruptcy.
IPA's Altman-Z score of -2.37 is on the low side compared to the rest of the industry. IPA is outperformed by 89.47% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that IPA is not too dependend on debt financing.
IPA has a worse Debt to Equity ratio (0.45) than 61.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z -2.37
ROIC/WACCN/A
WACC9.35%

2.3 Liquidity

IPA has a Current Ratio of 1.01. This is a normal value and indicates that IPA is financially healthy and should not expect problems in meeting its short term obligations.
IPA has a worse Current ratio (1.01) than 89.47% of its industry peers.
A Quick Ratio of 0.85 indicates that IPA may have some problems paying its short term obligations.
IPA has a worse Quick ratio (0.85) than 85.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.85

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.70% over the past year.
The Revenue has been growing slightly by 6.36% in the past year.
The Revenue has been growing by 17.55% on average over the past years. This is quite good.
EPS 1Y (TTM)26.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.87%
Revenue 1Y (TTM)6.36%
Revenue growth 3Y11.03%
Revenue growth 5Y17.55%
Sales Q2Q%3.39%

3.2 Future

IPA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.10% yearly.
Based on estimates for the next years, IPA will show a very strong growth in Revenue. The Revenue will grow by 20.73% on average per year.
EPS Next Y0.1%
EPS Next 2Y26.68%
EPS Next 3Y28.26%
EPS Next 5Y28.1%
Revenue Next Year0.58%
Revenue Next 2Y5.13%
Revenue Next 3Y14.4%
Revenue Next 5Y20.73%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

IPA's earnings are expected to grow with 28.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.68%
EPS Next 3Y28.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (1/6/2025, 5:20:01 PM)

After market: 0.5256 -0.02 (-4.09%)

0.548

+0.03 (+5.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-10 2024-12-10/bmo
Earnings (Next)N/A N/A
Inst Owners6.07%
Inst Owner Change0%
Ins Owners1.34%
Ins Owner ChangeN/A
Market Cap15.80M
Analysts80
Price Target5.1 (830.66%)
Short Float %0.59%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.17%
Min EPS beat(2)-35.01%
Max EPS beat(2)-3.32%
EPS beat(4)1
Avg EPS beat(4)-10.49%
Min EPS beat(4)-35.01%
Max EPS beat(4)5.29%
EPS beat(8)4
Avg EPS beat(8)1.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.51%
Min Revenue beat(2)-22.81%
Max Revenue beat(2)-2.22%
Revenue beat(4)1
Avg Revenue beat(4)-6.4%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)1.5%
Revenue beat(8)3
Avg Revenue beat(8)-3.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.67%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.75%
EPS NY rev (1m)2.15%
EPS NY rev (3m)-31.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.56%
Revenue NY rev (1m)-2.35%
Revenue NY rev (3m)-2.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.95
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 13
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.58
BVpS0.79
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.92%
ROE -84.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.27%
FCFM N/A
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%
F-Score2
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.64%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 0.85
Altman-Z -2.37
F-Score2
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)25%
Cap/Depr(5y)25.27%
Cap/Sales(3y)6.15%
Cap/Sales(5y)5.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.87%
EPS Next Y0.1%
EPS Next 2Y26.68%
EPS Next 3Y28.26%
EPS Next 5Y28.1%
Revenue 1Y (TTM)6.36%
Revenue growth 3Y11.03%
Revenue growth 5Y17.55%
Sales Q2Q%3.39%
Revenue Next Year0.58%
Revenue Next 2Y5.13%
Revenue Next 3Y14.4%
Revenue Next 5Y20.73%
EBIT growth 1Y18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.87%
OCF growth 3YN/A
OCF growth 5YN/A